ReviewClinical and molecular hepatology2023
Global incidence and prevalence of nonalcoholic fatty liver disease.
Review in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 439 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Metabolic Dysfunction Among Egyptian Patients with Chronic HBV
Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis(NASH), A Randomized Controlled Trial. FAST Trial"
Correlation Between Serum Adiponectin and Resistin Levels and Degree of Hepatic Fibrosis In Metabolic Dysfunction _Associated Steatotic Liver Disease (MASLD)With Type2 Diabetes Mellitus
Who cites it
439 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Applications of machine learning in the diagnosis of non-alcoholic fatty liver disease: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Association between periodontitis and non-alcoholic fatty liver disease in community-dwelling adults: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Diagnostic performance of ultrasound attenuation imaging in detecting hepatic steatosis.Journal of medical ultrasonics (2001) · 2026Pooled it
- Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study.Frontiers in clinical diabetes and healthcare · 2026Pooled it
- Pharmacological effects of dihydromyricetin in preclinical models of NAFLD: a systematic review and meta-analysis stratified by dose and duration.Frontiers in pharmacology · 2026Pooled it
- Efficacy of ursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease: an umbrella review of meta-analyses on liver enzymes.Frontiers in medicine · 2026Pooled it
- Liver Fat Quantification and Steatosis Grading in Fatty Liver Disease by Magnetic Resonance Imaging: Systematic Review and Meta-Analysis.Journal of gastroenterology and hepatology · 2025Pooled it
- Therapeutic potential of Akkermansia muciniphila in non-alcoholic fatty liver disease: a systematic review.BMC gastroenterology · 2025Pooled it
- Saroglitazar and vitamin E vs. lifestyle interventions in metabolic dysfunction associated steatotic liver disease: A 3-arm randomised study.The Indian journal of medical research · 2026Trial
- Moderate-Intensity Intermittent Walking Improves Liver-Related Biomarkers and Reduces Inflammation in Postmenopausal Women With Obesity: A Randomized Controlled Study.European journal of sport science · 2026Trial
- Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.Hepatology communications · 2026Trial
- Combined effect of metformin and ezetimibe on PPAR-γ and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes.Scientific reports · 2025 · on this mapTrial
- Association Between Allostatic Load, Genetic Susceptibility, and Liver Cancer Incidence: A Large-Scale Prospective Cohort Study.International journal of cancer · 2026Article
- Hypothyroidism and Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms, Clinical Links, and Therapeutic Implications.Current obesity reports · 2026Review
- Decoding dysbiosis: the role of gut microbiota in MASLD progression and emerging therapeutic interventions.Journal of physiology and biochemistry · 2026Review
- Vitexin-loaded phytosomes protect against high-fat diet-induced MASLD modulating PI3K/AKT/mTOR/SREBP-1c, Nrf2/HO-1, NF-κB/COX-2, and apoptotic pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Hepatocyte RAP1A Deletion Impairs Lipid Catabolism and Worsens Steatosis via Autophagy Activation.Diabetes & metabolism journal · 2026Article
- Oral Copaiba Oil-Resin Supplementation Reduces Plasma and Hepatic Oxidative Stress in Female and Male Hypothalamic-Obese Animals.Food science & nutrition · 2026Article
- Low-Dose, Long-TermInternational journal of molecular sciences · 2026Article
- Peroxisome proliferator-activated receptor gamma (PPARγ) as a mechano-metabolic transducer: coordinating lipid homeostasis through mechanical cues.Molecular biomedicine · 2026Review
379 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease worldwide. The estimated global incidence of NAFLD is 47 cases per 1,000 population and is higher among males than females. The estimated global prevalence of NAFLD among adults is 32% and is higher among males (40%) compared to females (26%). The global prevalence of NAFLD has increased over time, from 26% in studies from 2005 or earlier to 38% in studies from 2016 or beyond. The prevalence of NAFLD varies substantially by world region, contributed by differing rates of obesity, and genetic and socioeconomic factors. The prevalence of NAFLD exceeds 40% in the Americas and South-East Asia. The prevalence of NAFLD is projected to increase significantly in multiple world regions by 2030 if current trends are left unchecked. In this review, we discuss trends in the global incidence and prevalence of NAFLD and discuss future projections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.